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ObesityNS) complications resulting from diabetes is a problem that is gaining more
acceptance and attention. Recent evidence suggests morphological, electrophysiological and cognitive
changes, often observed in the hippocampus, in diabetic individuals. Many of the CNS changes observed in
diabetic patients and animal models of diabetes are reminiscent of the changes seen in normal aging. The
central commonalities between diabetes-induced and age-related CNS changes have led to the theory of
advanced brain aging in diabetic patients. This review summarizes the ﬁndings of the literature as they relate
to the relationship between diabetes and dementia and discusses some of the potential contributors to
diabetes-induced CNS impairments.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Diabetes mellitus is an endocrine disorder of carbohydrate
metabolism resulting from inadequate insulin release (insulin-
dependent diabetes mellitus, or type 1 diabetes; T1D) or insulin
insensitivity (non-insulin-dependent diabetes mellitus, or type 2
diabetes; T2D), both of which result in hyperglycemia if uncontrolled.
T1D is believed to occur in response to an autoimmune destruction of
insulin producing pancreatic β cells, whereas T2Dmay be triggered or
worsened by a number of factors including obesity, hypertension, and
other features of the metabolic syndrome. For many years it has been
well accepted that diabetes often results in microvascular and
macrovascular disease, leading to complications such as retinopathy,
peripheral neuropathy, stroke and coronary heart disease [1]. There is
now evidence illustrating that both T1D and T2D can also cause
complications within the central nervous system (CNS). Manifesta-
tions of diabetes-induced CNS complications may include structural
alterations or brain atrophy, as well as changes in electrophysiological
properties that ultimately result in deﬁcits in cognitive performance
[2]. These diabetes-induced CNS complications may be associated
with or exacerbated by cardiovascular disease, including hypertension
[3,4] and cerebral vascular complications [5–8]. Additional factors that
may contribute to diabetes-induced cognitive impairment include
disrupted insulin signaling and glucose homeostasis in the CNS [9].
Under normal circumstances glucose is the predominant meta-
bolic fuel source of the adult brain and is transported to the CNS1 803 733 1523.
ll rights reserved.from the periphery via facilitative glucose transporters [10]. Since
the brain can neither synthesize nor store glucose for extended
periods of time, it is essential that proper glucose regulation be
achieved in the periphery to ensure appropriate glucose transport to
the CNS [11], processes that may be disrupted in poorly-controlled
diabetes. Many brain structures, such as the hippocampus, are
extremely sensitive and responsive to changes in glucose home-
ostasis. For example, dysfunctional glucose regulation and/or
insufﬁcient insulin availability elicits neuronal synaptic reorganiza-
tion [12] and increased proliferation of astrocytes [13] in the
hippocampus of streptozotocin (STZ) diabetic rodents, an experi-
mental model of T1D. Additionally, glucose and insulin are both
instrumental regulators of cognitive function [14–21], further
supporting the hypothesis that inefﬁcient regulation of these two
factors may contribute to cognitive deﬁcits in diabetes phenotypes.
The discrete etiologies and pathological manifestations of these
subtypes of diabetes provide insight as to the differential deleterious
effects of T1D and T2D on cognition. While it could be argued that
these impairments may not hinder daily cognitive functioning in
diabetic individuals, these alterations in cognition and brain structure
may over time lead to an acceleration of CNS aging [22] or an
increased risk for age-related diseases such as Alzheimer's disease
(AD) [23]. Accordingly, this reviewwill examine the diabetic brain and
its associated changes in both T1D and T2D, with particular emphasis
on diabetes-induced deﬁcits in the structural and functional proper-
ties of the hippocampus. Additionally, this review will highlight the
potential contributors to diabetes-induced brain changes and will
provide a general discussion of how several diabetes-associated CNS
changes correlate with an increased risk of AD and advanced brain
aging in both the clinical and pre-clinical settings. Although animal
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humans, data from non-human studies will be referred to and
acknowledged for contributions made in providing insight into
mechanisms relevant to the clinical setting.
2. The relationship between cognitive decline and diabetes
There is an increasing appreciation that cognitive decline occurs in
both T1D and T2D. However, there are differences concerning the
relative degree of cognitive dysfunction and the way in which these
cognitive abnormalities are manifested in the two sub-types of
diabetes. For example, although theremay be commonalities between
the underlying mechanisms involved in diabetes-induced cognitive
impairments, many studies have shown that T1D is more likely to be
associated with psychomotor slowing and reductions in mental
efﬁciency [24], while cognitive deﬁcits in T2D are often in the areas
of psychomotor efﬁciency, attention, learning and memory and
executive function [25]. Moreover, some studies suggest that
diabetes-induced CNS complications occur more rapidly in T2D than
in T1D. For instance, in a comparative study of cognitive function,
those with more than 30 years of T1D had comparable cognitive
proﬁles toT2D patients with seven years of disease duration [26]. Also,
when compared to T2D patients, T1D patients had better brain
magnetic resonance imaging (MRI) ratings [26], which measure
changes in brain volume, silent infarcts and white matter lesions
(WML). Hyperintense lesions, as measured by T2-weighted and
proton density MRI, occur in white matter (referred to as white
matter hyperintensities, WMH or WML) as well as in gray matter
[27,28]. The clinical signiﬁcance of WML remains undetermined
[28,29]; however, WML have been associated with diabetes, AD,
normal aging, impairments in cognition, and accelerated cognitive
decline [27,28,30–33]. As such, increases in WML in diabetic
individuals may lead to the development of a cognitive phenotype
similar to that of aged individuals.
The differential effects of T2D and T1D upon cognition raise the
question of the underlying causes for the cognitive differences in these
two diseases. One potential clue as to why T1D and T2D may differ in
the progression of cognitive impairment is a potential interaction
between diabetes and age [34,35]. This theory is consistent with the
fact that T2D is more prevalent with increasing age and the
observation by Biessels and Kappelle that clinically relevant decreases
in cognitive function are more likely to occur in elderly T2D patients
[36]. Additionally, T1D is a disease that often affects individuals before
the age of 18 [37] which presents the possibility that developmental
compensations may contribute to the less severe cognitive deﬁcits
observed in T1D patients when compared to T2D patients. Another
possible explanation for the differential effects of T1D and T2D upon
cognitive function is insulin resistance, a feature more prevalent in
T2D than in T1D. In support of this hypothesis, insulin resistance was
identiﬁed as the best predictor of T2D diagnosis in a study of pre-
diabetic individuals [38]. Additionally, insulin resistance is associated
with a host of conditions including, hyperglycemia, hyperinsulinemia,
hypertension, dyslipidemia, and increased central adiposity collec-
tively termed the metabolic syndrome [39]. Many features of the
metabolic syndrome may contribute to cognitive impairment inde-
pendently or in combination with one another [39]. Although the
incidence of cognitive deterioration is more prevalent in older T2D,
younger T2D and T1D patients are not immune to the deleterious
consequences of diabetes upon brain structure and function.
3. Type 1 diabetes and cognitive impairment
T1D is a life-long disorder usually diagnosed in younger individuals
(50–60% younger than 18 years of age) [37] and therefore raises
concern regarding how this disease and its treatment may impact
cognitive performance. In this regard, it has been reported thatchildren with T1D show impairment on tasks of declarative memory
compared to age matched non-diabetic controls [40]. Typically, T1D is
treated in either a conventional or intensive manner with exogenous
insulin [1]. Insulin treatment increases the risk of hypoglycemic
episodes [1,41], and increases the potential for cycling between
hypoglycemia and hyperglycemia, both of which can be harmful to the
brain, especially the developing brain [42–44]. Additionally, both
hyperglycemia and hypoglycemia are known to cause acute cerebral
dysfunction [45] and are associated with decline in intellectual
performance [39]. While some investigators report no independent
correlation between preceding severe hypoglycemic events and
cognitive function in adult T1D patients [46], several clinical studies
report that hypoglycemic events negatively affect cognition. For
example, Hershey et al. reported that children with more frequent
and earlier onset of hypoglycemic events had worse performance on
tests of short and long delay spatial memory than did other tested
groups [47]. A higher frequency of hypoglycemic events during a
relatively short period of time, as is more often the case in diabetic
children than adults, could account for discrepancies between studies.
Nonetheless, these studies emphasize the importance of maintaining
good glycemic control for diabetes patients.
It is important to note that although T1D patientsmay perform less
well on some cognitive tasks when compared to control subjects,
scores for diabetes patients are often within the normal cognitive
range [48]. In a study comparing young to middle aged T1D patients
with age-matched controls, the diabetic persons performed more
poorly on tests of executive function, short term memory, psycho-
motor efﬁciency and a measure of mental efﬁciency; however, all
subjects scored within a normal cognitive range [49]. These results
imply that although there are deﬁcits in cognition in T1D, these
deﬁcits are mild and may not fall below ratings of the general
population. However, the potential unfortunate outcome of these
‘mild’ cognitive deﬁcits in T1D patients is a predisposition for more
rapid deterioration of cognitive function in later life. Indeed,
cumulative CNS complications in the hippocampus may lead to
cognitive decline, as well as increased risk for neurological comorbid-
ities [35,50].
3.1. Diabetes and the hippocampus in type 1 diabetes
The hippocampus is an important structure for the integration of
learning and memory in the mammalian CNS [51] and is particularly
sensitive to changes in glucose homeostasis. For example, improper
glucose homeostasis may impact the electrophysiological properties
of hippocampal neurons. In particular, studies performed on rodent
models of T1D and models of improper glucose regulation show
dysfunctional synaptic plasticity with speciﬁc deﬁcits in long-term
potentiation (LTP) and long-term depression (LTD) [52–54]. Typically
these animal models have impairments in LTP and an enhancement of
LTD when compared to controls. These electrophysiological changes
may be an underlying contributor to some of the impairments
exhibited by diabetic animal models on cognitive performance.
Indeed, STZ diabetic rats that exhibit these electrophysiological
changes in LTP and LTD perform less well on spatial memory tasks
when compared with control rats [55].
Clinical imaging studies have provided insight into additional
factors that may contribute to cognitive deﬁcits observed in T1D
patients, including structural and morphological changes in the
hippocampus. In this regard, the odds for better performance on
delayed memory tasks were greater in T1D patients with no
periventricular WMH [49]. However, this study as well as others
identiﬁed no overall changes in brain matter composition or volume
in T1D patients [43,48,49]. Conversely, some reports have identiﬁed
changes in brain structures and brain volume in T1D [56–59]. The
discrepancies in brain imaging studies of T1D may be related to
patient age, age of diabetes onset, hypoglycemic events, or differences
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onset may be one of the most critical contributors to CNS structural
abnormalities [58], although this may be a secondary effect related to
the number of hypoglycemic and/or hyperglycemic events experi-
enced by the patient. Structural analyses in the hippocampus of
experimental models of T1D have yielded more consistent ﬁndings.
In histological studies, STZ diabetic rats display morphological
changes in the hippocampus, including dendritic atrophy in the CA3
pyramidal neurons [12]. In addition, T1D rats exhibit redistribution of
the synaptic proteins synaptophysin and post-synaptic density 95
(PSD-95), which could be indicative of ongoing synaptogenesis in the
hippocampus of STZ rats [60]. Collectively, these clinical and pre-
clinical data illustrate that the extent of cognitive impairment and
brain morphology abnormalities in T1D remains to be unequivocally
determined. However, the literature to date suggest that structural
changes, which may underlie cognitive decline, are likely occurring in
T1D patients, effects that may have detrimental consequences over
extended periods of time.
4. Type 2 diabetes and cognitive impairment
A number of studies have examined the relationship between T2D
and cognition. Some studies suggest that cognitive performance does
not differ between T2D patients and non-diabetic controls when the
inﬂuence of age, premorbid IQ, bodymass index (BMI) and depression
are taken into account [61]. However, many clinical and pre-clinical
studies contradict this ﬁnding and support the concept that T2D is
associated with cognitive decline. In this regard, T2D patients have
been identiﬁed as having mini-mental state examination (MMSE, a
measure of cognitive ability) scores in the impaired range when
compared to age-matched controls [62]. Moreover, lower cognitive
scores on performances of general cognition, verbal memory, and
category ﬂuency have also been reported inmen andwomenwith T2D
[63]. These ﬁndings are in agreement with other studies suggesting an
increased occurrence of cognitive impairment in older T2D individuals
[64]. More recently, Convit and coworkers reported that the cognitive
deﬁcits in T2D patients may be more selective for hippocampal-
related memory performance and that these deﬁcits are correlated
with the degree of glycemic control [65]. These clinical data are
supported by observations from animal models of T2D. For instance,
the db/db mouse exhibits deﬁcits in the water maze, a hippocampal-
dependent spatial learning task [66]. Moreover, our previous studies
revealed that type 2 Zucker fa/fa diabetic rats perform more poorly
compared to their lean littermates in the variable-interval delayed
alternation test of learning andmemory [67]. It can be concluded from
these studies that T2D subjects experience deﬁcits in hippocampal-
based cognitive performance, deﬁcits that may be attributed to
changes in brain structure and volume.
4.1. Hippocampal structure and function in type 2 diabetes
A number of studies suggest that patients with T2D are more likely
to have structural brain abnormalities [64,68], such as cerebral infarcts
[69], when compared with T1D patients and non-diabetic individuals.
In an MRI study of subjects with vascular disease, patients with T2D
were more likely to have a smaller brain parenchymal fraction and
more WMH than patients with vascular disease but without diabetes
[33]. Alternatively, a review of imaging studies measuring structural
brain changes in diabetic patients found no consistent data concern-
ingWML but found a correlation between brain atrophy and T2D [70].
In particular, the hippocampus and other temporal lobe structures
appear to have high susceptibility to diabetes-associated atrophy
[65,69,71], and most studies of T2D-related structural rearrangement
provide evidence for the occurrence of some identiﬁable CNS damage,
especially within the hippocampus [50]. Changes in hippocampal
morphology may be accompanied by electrophysiological changes inT2D, which may contribute to cognitive decline. For example,
electrophysiological deﬁcits are observed in the hippocampus of
experimental models of T2D such as the db/dbmouse and the Zucker
rat [66,72]. In the clinical setting, a study of middle aged T2D patients
identiﬁed differences between right, left and overall P300 wave
latencies in diabetics compared to controls [62]. The P300 wave is a
cortical neurophysiological characteristic reﬂecting the speed of
neuronal events underlying information processing and appears to
be strongly associated with attention and short-term memory.
Changes in P300 are important to note due to the fact that T2D-
induced cognitive changes often include deﬁcits in attention and
learning and memory [25]. Interestingly, changes in P300 wave are
also a trait observed in normal aging [73], which provides a potential
functional deﬁcit common to both diabetes and normal brain aging.
Overall, these studies provide data indicating that cognitive decline is
a neurological consequence of T2D that may be partly attributable to
structural rearrangement and changes in the electrophysiological
properties of hippocampal neurons. Importantly, these neurological
consequences of diabetes appear to parallel those observed in the
aging brain.
5. Aging, neurodegenerative diseases and diabetes
5.1. The normal aging brain
The process of normal aging is characterized by decreased ability to
remember new facts, decline in cognitive performance, structural and
morphological brain changes, modiﬁcations in electrophysiological
properties, and increased risk of diabetes and insulin resistance [73,74].
There is a trend for a slight decrease in brainweight and volume in aged
people [74] and a correlation between atrophy rates and decline in
cognitive ability [75,76]. In a six year longitudinal study of older
individuals, brain atrophy was reported to be most correlated with age,
heavy drinking and glycosylated hemoglobin index (HbA1c), an
indicator of long term glycemic control [77]. Reorganization of the
structural and chemical balance of the hippocampus in aged people and
animals can be correlated to age-related memory deﬁcits and changes
in synaptic plasticity [73,78–80]. For example, with increasing age,
there is a decrease in the number of synapses in the dentate gyrus and
speciﬁc synapse loss of cortical inputs to the hippocampus in both
humans and animals [73]. In aged rats, the hippocampus has
approximately one-third fewer synaptic contacts from the entorhinal
cortex when compared to younger rats [73]. In addition to decreased
synapse number, hippocampal interneuron populations are decreased
in the aged brain; speciﬁcally, GAD67 immunoreactive interneurons are
decreased in the CA1 region of the hippocampus of old rats [81]. These
data compliment reports of decreases in speciﬁc interneuronal
populations in other hippocampal regions such as the hilus [82].
Decline in hippocampal interneuron populations may have functional
consequences since interneurons have been shown to be crucial for a
variety of cognitive functions including memory [83]. As described
above, many of these changes observed in the aging hippocampus are
also seen in diabetic patients and animal models of diabetes, changes
that may predispose diabetic subjects to neurodegenerative diseases
such as AD. The commonalities between the diabetic brain and the
aging brain support the idea that diabetes induces advanced brain
aging, especially in T2D patients [84]. However, advanced age is a risk
factor for both diabetes and cognitive decline. As a result, it is
challenging to differentiate between these factors in order to determine
whether diabetes induces brain aging or interacts with normal aging to
create an exacerbated phenotype. A concept referred to as “the brain
reserve hypothesis” may provide insight into this question.
The brain reserve hypothesis was ﬁrst suggested to explain
incongruence between pathological brain damage and cognitive and
functional performance in older individuals [85]. This hypothesis is
based on the theory that individuals with higher levels of education
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does not suffer in response to brain atrophy or structural changes [85].
A modiﬁed theory of brain reserve in relation to diabetes has been
discussed by Ryan and Geckle, which proposes that older individuals
have less brain reserve making them more susceptible to diabetes-
induced CNS changes [84]. It is possible that this revised hypothesis is
not only applicable to older diabetic patients but perhaps to all
diabetic patients irrespective of age. If this hypothesis is correct,
diabetes patients would be more susceptible to CNS insults arising
from diabetes and less capable of adapting in order to reduce or
eliminate cognitive deﬁcits. The addition of an increasing number of
insults, such as the features of the metabolic syndrome in T2D or
hypoglycemic episodes in T1D patients, would further increase CNS
vulnerability. As such, poorly controlled diabetes would create a
neuronal milieu inwhich diabetes patients are more vulnerable to the
aging process and age-related diseases such as AD.
5.2. Diabetes and age-related comorbidities: Alzheimer's disease
Alzheimer's disease (AD) is the most common form of dementia in
the United States [86,87]. Risk factors for AD may include age,
genetics, a variety of cardiovascular complications and diabetes [88].
The onset of AD is generally subtle, followed by a progressive decrease
in cognitive function characterized by memory loss [87,89]. Histolo-
gically, AD is identiﬁed by an abundance of neuritic plaques and
neuroﬁbrillary tangles in areas of the cerebral cortex, hippocampus
and other temporal lobe structures of postmortem tissue [87,90].
Neuritic plaques are formed from an accumulation of amyloid-β (Aβ)
peptide which is produced by cleavage of amyloid precursor protein
(APP) [87]. Neuroﬁbrillary tangles are composed of abnormally
hyperphosphorylated tau protein, an axonal protein that promotes
microtubule assembly and stability [87]. Hyperphosphorylation
disrupts proper tau function and may lead to synapse dysfunction,
neuron degeneration and cognitive impairment [91].
Some clinical and epidemiological studies have demonstrated an
association between diabetes and the development of comorbid AD.
Data from the Religious Orders study, a study of aging in Catholic
priests, nuns and brothers across the US, show a 65% increased risk of
developing clinical manifestations of AD in diabetic patients com-
pared to non-diabetic controls [23], ﬁndings that are consistent with a
number of other studies [4,92–94] but not all [95]. In addition, some
researchers have identiﬁed an association between borderline non-
overt diabetes and increased AD risk [96]. One plausible explanation
for potential increased risk of AD in diabetes is insulin resistance.
Plasma insulin levels are elevated in type 2 patients and in AD patients
[88,92,97], which presumably reﬂects insulin resistance. Additionally,
in AD patients, administration of insulin increases plasma levels of Aβ
[98], which would potentially increase CNS levels of Aβ that could
accumulate into neuritic plaques. In control non-demented subjects,
insulin causes a decrease in plasma Aβ levels [98], further supporting
differences in the insulin system of AD patients compared to non-AD
subjects. Unlike the increases in plasma insulin levels, there is a
decrease in cerebrospinal ﬂuid (CSF) levels of insulin in AD patients
compared to non-AD controls and a positive correlation between CSF
insulin and dementia severity in AD [97]. Such results would support
the idea that insulin resistance may be a contributor to cognitive
impairment and dementia in AD patients.
Some researchers suggest that insulin aids in the clearance of Aβ,
at least in the periphery [98], but others support the concept that
insulin leads to the release of intracellular Aβ, thereby increasing
secretion into the extracellular space and facilitating Aβ accumulation
[88]. Under physiological conditions, insulin signaling cascades have
been implicated in the regulation of tau phosphorylation [99]. Brieﬂy,
insulin signaling leads to the activation of phosphoinositide 3-kinase
(PI3K), which phosphorylates and activates Akt. Activated Akt in turn
phosphorylates and inactivates the cytoplasmic enzyme glycogensynthase kinase-3β (GSK3β). In the brain, GSK3β is one of the kinases
involved in the phosphorylation of tau [99]. In the normal brain,
insulin signaling activation reduces the phosphorylation state of tau,
whereas deﬁcits in insulin signaling could cause hyperphosphoryla-
tion of tau [99]. Whether these mechanisms contribute to hyperpho-
sphorylation of tau in AD patients or diabetes patients remains to be
veriﬁed. However, hyperphosphorylation of tau is observed in
experimental models of diabetes. In a study of Alzheimer-associated
pathologies in animal models of diabetes, both T1D and T2D rats
exhibited decreases in phosphorylated Akt and phosphorylated GSK-
3β [100], which may have contributed to the development of
histological AD features. Additionally, tau is hyperphosphorylated in
STZ diabetic mice [101–103]. Moreover, histological studies from our
lab identiﬁed hyperphosphorylated tau immunoreactivity in the
hippocampus of fatty Zucker rats, AD-like pathology that is not
observed in lean control rats (Fig. 1).
There are a limited number of human postmortem studies that
have examined histological features of AD in the diabetic brain and
these studies have yielded inconsistent ﬁndings. Some studies report
no association [104,105], while another study reports a negative
correlation between diabetes and the presence of neuritic plaques and
neuroﬁbrillary tangles [106]. A number of possibilities could explain
the discrepancy between postmortem and clinical data relating AD to
diabetes. For example, diabetic individuals with comorbid AD may be
less likely to survive to an older age and thereforemay not be included
in these postmortem studies [106]. Additionally, there is the
possibility that diabetes does not increase the risk of developing
histological features of AD but instead creates a cognitive phenotype
that resembles the clinical symptoms of AD, a phenotype which may
be more pronounced in individuals of older age. In support of this
concept, data from the Religious Orders study show a correlation
between diabetes and clinical symptoms of AD [23] while no
correlation was later found between postmortem histopathological
AD features and diabetes in this same population [104]. Nonetheless,
as detailed above, some features associated with AD are observed in
diabetic patients and would support the idea of diabetes increasing
the risk of AD or AD-like symptoms. The association between
increased risks of developing mild cognitive impairment (MCI) or
AD in diabetes patients requires further analysis, including additional
post-mortem studies assessing histopathological features such as
hyperphosphorylated tau. It is crucial that further investigation be
continued in order to elucidate the mechanistic mediators that
increase neuronal vulnerability and thereby facilitate cognitive
decline and progression of AD symptomatology in diabetic patients.
6. Potential contributors to diabetes-induced brain aging
6.1. Insulin and glucose
The discovery of centrally located insulin receptors [107,108] has
lead to a greater appreciation of the multi-faceted functions of insulin
within the CNS. The expression of insulin receptors in the hippocam-
pus has driven the hypothesis that insulin is an important contributor
to or regulator of cognitive function [109,110] a theory supported by
clinical evidence. For example, chronic intranasal insulin administra-
tion improves cognitive performance in both AD and non-demented
individuals [17,88,111–113], and acute insulin administration has been
shown to improve declarativememory in AD patients [114]. Moreover,
administration of the insulin sensitizer, rosiglitazone, ameliorates
cognitive decline in non-diabetic AD patients [115]. Rosiglitazone-
induced cognitive improvement is also observed in animal models of
AD [116], which may be mediated in part through increases in
dendritic spine density, an effect of rosiglitazone observed in primary
cortical cultures [117]. Insulin is also known to exert direct and
indirect effects over various neurotransmitter systems. For example,
insulin increases N-methyl-D-aspartate (NMDA), α-amino-3-
Fig. 1. Hyperphosphorylation of tau is increased in the hippocampus of Zucker type 2 diabetic rats. Representative photomicrographs demonstrate an absence of
hyperphosphorylated tau immunoreactivity in the dentate gyrus (Panel A) and the CA3 region (Panel C) of lean control rats. Conversely, hyperphosphorylated tau immunoreactivity
is signiﬁcantly increased in the dentate gyrus (Panel B, arrow heads) and the CA3 region (Panel D, arrow heads) of fatty Zucker diabetic rats. This AD-like pathologymay contribute to
the development of behavioral deﬁcits observed in this experimental model of type 2 diabetes.
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nobutyric acid (GABA) receptor surface expression [118–120], and
indirectly regulates particular neurotransmitters, such as epinephrine
[18,121–123]. Insulin also modulates basal synaptic transmission
[124–126] and restores normal synaptic plasticity in the hippocampus
of animal models of diabetes [55]. Additionally, cognitive training
strengthens insulin signaling in the hippocampus of non-diabetic rats
[127], effects that may further enhance the functional activities of
neurotransmitters that are critical for synaptic plasticity and cognitive
function. Under pathological conditions, previous studies have
revealed that hyperglycemia, endocrine dysfunction, deﬁcits in
hippocampal plasticity and behavioral performance observed in
experimental models of diabetes are inhibited by insulin replacement
[55,128]. Such results suggest that decreases in insulin receptor (IR)
activity may be an initiating factor producing deﬁcits in hippocampal
plasticity and ultimately cognitive decline.
Another important contributor to brain function, especially as it
relates to cognition, is glucose. In this regard, fasting plasma glucose
levels were negatively correlated with episodic memory and recall in a
study of normal healthy women [129]. Also, glucose administration
improves cognitive performance in people and animals irrespective of
pre-existing cognitive impairments [19,20,114,130,131]. During hippo-
campal-dependent cognitive tasks, extracellular levels of glucose are
decreased in the hippocampus of rodents, implying increased glucose
uptake and utilization by cells [15]. The intimate connection between
glucose and cognition [129,132] reinforces the importance of maintain-
ing the delicate balance of glucose levels within the brain. Studies in
experimental models of diabetes provide additional support for the
importance of tight glycemic control. For example, moderate recurrent
hypoglycemia improved performance on a hippocampal dependent
cognitive task in the euglycemic state in male rats, as compared to
control animals. However, during acute hypoglycemia, recurrent hypo-
glycemic animals performed no better than chance on a maze task
[133]. These data suggest that familiarity with the experience of
hyperglycemia or hypoglycemia may cause the brain to become more
efﬁcient at utilizing glucose and other means of energy during cognitivetasks, but only when sufﬁcient glucose is available. Although these data
suggest that a more constant glycemic index is perhaps better than
ﬂuctuations between glycemic states, harmful CNS consequences may
nonetheless accompany a non-euglycemic environment, including
blood–brain barrier dysfunction [122], deep subcortical white matter
lesions and other structural deﬁcits [43,64]. Although the data on the
effects of glycemic control show a bit of discrepancy, overall, it appears
that bouts of hypoglycemia and hyperglycemia make a signiﬁcant
contribution to cognitive performance impairments via a variety of
mechanisms [134].
6.2. Advanced glycation end products and oxidative stress
In addition to altering cognitive performance, poor glycemic
control increases the accumulation of advanced glycation end
products (AGE) [135], products formed by the non-enzymatic reaction
between sugars and amino groups, and oxidative stress in the brain,
whichmay lead to cellular andmolecular damage [136]. In this regard,
AGE and oxidative stress have both been identiﬁed as potential
contributors to diabetes-induced brain aging [22,137]. Accumulated
AGE are present in normal aging and in certain pathological conditions
such as AD and diabetes [138–141]. Among the actions of AGE are
effects on extracellular matrix proteins and basement membrane
components which can cause or facilitate vascular complications
[135,142]. Additionally, AGE generation increases proinﬂammatory
mechanisms in the vessels that enhance oxidative stress. An increase
in oxidative stress leads to AGE accumulation and thus creates an
unremitting cycle [140] which may contribute to a host of complica-
tions and imbalances.
In physiological conditions there is a delicate balance between the
synthesis of oxygen free radicals and the activities of anti-oxidant
pathways to protect the organism; an imbalance of the oxidant/anti-
oxidant equilibrium favoring the former creates a situation of
oxidative stress [143]. Studies from animal models have strengthened
the relationship between oxidative stress, aging and cognitive
performance. For example, increases in oxidative stress in the rat
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mance in hippocampal-dependent learning and memory paradigms,
such as the Morris water maze [143–145]. During aging, antioxidant
enzyme activity and expression decreases [146–148], suggesting that
oxidative status may shift towards accumulation of oxidative stress
products. There are similar imbalances in oxidant/anti-oxidant path-
ways in animal models of diabetes [9]. The free radical hypothesis of
aging proposes that aging is the result of random harmful effects on
tissue due to oxygen free radicals [149,150], a hypothesis that may be
applicable to diabetic individuals as well. As such, deleterious AGE
accumulation and imbalances in oxidative stress status may be among
the etiological factors that contribute to the pathogenesis of age-
related and diabetes-induced cognitive impairments. The potential for
disruption of proper AGE metabolism and oxidative stress status in
diabetes [137] provide additional explanations as to how diabetes
might worsen or accelerate the brain aging process.
6.3. HPA axis dysfunction
Many pathological conditions are associated with hypothalamic–
pituitary–adrenal (HPA) axis dysregulation, including diabetes (For
review see [9]). The relationship between glucocorticoids (GCs) and
obesity, a common feature in T2D patients, is relevant in terms of
induction of insulin resistance. In this sense, lipolysis induced by GCs
increases free fatty acid levels in blood, which in turn causes
hyperglycemia through the stimulation of hepatic gluconeogenesisFig. 2. Potential mechanistic mediators of diabetes-induced brain aging. The complex path
glucose homeostasis, dysregulation of hypothalamic–pituitary–adrenal (HPA) axis function, a
hippocampus include dendritic atrophy, changes in synapse formation, electrophysiologica
hyperphosphorylated tau. Additional pathological consequences that contribute to cognitiv
development of insulin and/or leptin resistance in the hippocampus. These factors, in co
mediators such as the pro-inﬂammatory cytokines, act in an additive or synergistic fashion t
the development of age-related disorders such as mild cognitive impairment and AD. See tand a reduction in glucose uptake by competing with glucose for
oxidation [151]. Consequently, a compensatory increment in insulin
secretion leads to hyperinsulinemia, downregulation of insulin
receptors and insulin resistance. Short-term corticosterone (CORT)
administration to rats produces peripheral insulin resistance and
also decreases insulin sensitivity in the hippocampus, including
decreases in insulin-stimulated translocation of the insulin sensitive
glucose transporter GLUT4 [152]. Interestingly, adrenalectomized STZ
rats and db/db mice provided low dose of CORT replacement exhibit
improved spatial memory and novel object recognition compared to
sham operated animals and adrenalectomized animals given high
levels of CORT replacement [153]. Such results support the notion
that HPA axis dysfunction and/or exposure to elevated glucocorti-
coid levels contributes to the cognitive deﬁcits observed in diabetic
animals. It appears that most, if not all, of the comorbidities
associated with diabetes or insulin resistance are characterized by
HPA axis dysfunction [154,155]. Although cause and effect have not
been determined in many of these situations, these ﬁndings may
place impairments in HPA axis function at the center of diabetes-
induced advanced brain aging.
6.4. Obesity
Ongoing epidemiological studies by the Centers for Disease
Control estimates that more than 60% of the adult US population
may be categorized as either overweight or obese [156]. Since thereophysiological features of diabetes may include decreases in insulin activity, impaired
nd hyperleptinemia, among others. The consequences of these pathophysiologies in the
l deﬁcits, as well as the appearance of Alzheimer's disease-like histopathology, such as
e decline in diabetic subjects may include changes in oxidative stress status and the
mbination with other pathological features such as microvascular complications and
o accelerate brain aging in diabetic subjects, thereby increasing patient vulnerability for
ext for details.
450 S.A. Wrighten et al. / Biochimica et Biophysica Acta 1792 (2009) 444–453is a positive correlation between risk of T2D development and
obesity [157], understanding the relationship between obesity and
cognitive function is an important health care issue. In this regard,
obesity has been both positively and negatively correlated with
dementia in older individuals [158–160]. However, among middle-
aged people there is a common trend for obesity to be negatively
correlated with cognitive performance [3,161]. Obesity-related CNS
abnormalities may be due to obesity-induced insulin resistance and/
or impaired glucose tolerance [157,162], as described in previous
sections. In addition, obesity may contribute to dementia and other
cognitive impairments by increasing the incidence of vascular
pathologies [163,164]. An additional consideration in obesity phe-
notypes is the potential for increases in plasma levels of adipocyte-
derived hormones, such as leptin, that may have deleterious
consequences on the CNS.
Leptin is synthesized and secreted by adipocytes and is transported
across the blood–brain barrier (BBB) via a saturable transport system
[165]. The actions of leptin in the hypothalamus are well described,
especially in relation to normal metabolism and in pathophysiological
settings such as diabetes and obesity phenotypes [166]. There is now a
growing literature to support a role for leptin in the facilitation of
hippocampal synaptic plasticity [167]. For example, studies by Harvey
and co-workers determined that leptin enhances hippocampal
excitability via NMDA receptor mediated mechanisms and regulates
hippocampal plasticity by converting short-term potentiation into LTP
in young rats [168]. Confocal immunoﬂuorescence analyses also
determined that leptin regulates the morphological features of
primary hippocampal cultures, including the motility of dendritic
ﬁlopodia [169]. These structural and functional enhancements of
hippocampal plasticity may contribute to leptin's ability to improve
hippocampal-dependent behavioral performance [170–172]. Alterna-
tively, genetic mutations that result in disrupted leptin signaling
such as in the db/db mouse and the Zucker fa/fa rat are associated
with reductions in LTP [66,72] and impaired performance of
hippocampal-dependent tasks [66,67]. Such results indicate that
decreases in leptin signaling contribute to deﬁcits in hippocampal
synaptic plasticity and suggest that leptin resistance, a well described
phenomenon in the hypothalamus, may also be observed in the
hippocampus in diabetes/obesity phenotypes.
7. Conclusions
Through ﬁndings from both human and animal studies, the
underlying mechanisms involved in diabetes-induced CNS complica-
tions are coming under greater scrutiny and becoming better
appreciated. It is extremely difﬁcult to decipher a causal relationship
between many of the endocrine and metabolic changes observed in
diabetes and to appoint speciﬁc contributions of each factor. It is
unlikely that any single factor is solely responsible for the CNS
complications in diabetic subjects. Rather, a variety of factors likely
act in additive or synergistic ways to impair neuronal homeostasis,
increase neuronal vulnerability and eventually contribute to cogni-
tive decline (see Fig. 2). Since some studies suggest that diabetic
patients exhibit cognitive performance that is within the normal
range, the magnitude or importance of memory decline in diabetic
patients is often debated. However, the combination of the structural
and functional changes within the hippocampus that elicit subtle
decreases in cognitive function may be progressive and silently lead
to increased risk of age-related neurological disorders. Indeed, the
deleterious consequences of diabetes undoubtedly accumulate over
time and ultimately produce detrimental effects in the CNS. Such
realities emphasize the importance of patient education as it relates
to maintaining a healthy life style through diet, exercise and
medication. Additionally, there is a continued need for clinicians
and pre-clinical scientists to identify the factors that are involved in
the etiology and progression of the neurological complications ofdiabetes, as well as identify the fundamental basis that may cause
diabetes patients to be more susceptible to develop comorbid MCI or
AD. Therefore, one critical mission of ongoing research is the
identiﬁcation of these mechanistic mediators, which may lead to
the development of novel therapeutic strategies to prevent or
reverse the neurological consequences of diabetes in the CNS.
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